The estimated Net Worth of Steven Simonson is at least $978 Tysiąc dollars as of 15 March 2022. Steven Simonson owns over 5,000 units of Windtree Therapeutics stock worth over $254,986 and over the last 6 years he sold WINT stock worth over $0. In addition, he makes $722,907 as Senior Vice President and Chief Medical Officer at Windtree Therapeutics.
Steven has made over 3 trades of the Windtree Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of WINT stock worth $5,000 on 15 March 2022.
The largest trade he's ever made was buying 5,000 units of Windtree Therapeutics stock on 15 March 2022 worth over $5,000. On average, Steven trades about 702 units every 66 days since 2019. As of 15 March 2022 he still owns at least 83,602 units of Windtree Therapeutics stock.
You can see the complete history of Steven Simonson stock trades at the bottom of the page.
Dr. Steven G. Simonson M.D. serves as Senior Vice President and Chief Medical Officer of the Company. Dr. Simonson brings to us over 25 years of medical practice and pharmaceutical industry clinical trial experience with a significant background in pulmonary critical care and developing respiratory drugs, including preclinical, first time into man and phases 1-4, and IND, NDA and sNDA experience. Dr. Simonson spent 15 years at AstraZeneca Pharmaceuticals in areas of medical and clinical leadership primarily in the pulmonary and infection therapeutic areas. He has been involved in or led several successful IND and NDA filings. He spent the next two years as Vice President of Clinical Development at Agennix, Inc., a biopharmaceutical company primarily focused in oncology and sepsis, leading programs including studies of talactoferrin in necrotizing enterocolitis. Most recently, Dr. Simonson was an Executive Director in the Molecule Development Group at Covance, a biopharmaceutical development services company, where he applied his experience to developing clinical development programs for small and mid-size biotech and pharmaceutical companies. Dr. Simonson completed training in internal medicine followed by a fellowship in pulmonary and critical care medicine at Duke University Medical Center. He then held several faculty appointments at Duke in the departments of Anesthesiology and Medicine, including the divisions of Pulmonary and Critical Care Medicine. He is a Fellow of the American College of Chest Physicians, and author or co-author of multiple peer reviewed publications, abstracts, posters and chapters. Dr. Simonson received his medical degree from the Medical College of Wisconsin, and his Master of Health Sciences degree in Biometry from the Duke University School of Medicine.
As the Senior Vice President and Chief Medical Officer of Windtree Therapeutics, the total compensation of Steven Simonson at Windtree Therapeutics is $722,907. There are 2 executives at Windtree Therapeutics getting paid more, with Craig Fraser having the highest compensation of $1,063,640.
Steven Simonson is 61, he's been the Senior Vice President and Chief Medical Officer of Windtree Therapeutics since 2017. There are 8 older and 8 younger executives at Windtree Therapeutics. The oldest executive at Windtree Therapeutics, Inc. is Mary Templeton, 73, who is the Senior Vice President, General Counsel and Corporate Secretary.
Steven's mailing address filed with the SEC is 2600 KELLY ROAD, SUITE 100, WARRINGTON, PA, 18976.
Over the last 6 years, insiders at Windtree Therapeutics have traded over $1,982,541 worth of Windtree Therapeutics stock and bought 6,849,036 units worth $20,224,921 . The most active insiders traders include James Huang, Pharmaceutical Holdings Ltd... oraz Ii Investments Ltd Lph. On average, Windtree Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $425,323. The most recent stock trade was executed by Craig Fraser on 27 September 2023, trading 2,500 units of WINT stock currently worth $2,550.
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
Windtree Therapeutics executives and other stock owners filed with the SEC include: